Vfend and Gaviscon drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Vfend (voriconazole) and Gaviscon (aluminum hydroxide; magnesium trisilicate). Common drug interactions include fall among females and abdominal pain among males.

The phase IV clinical study analyzes what interactions people have when they take Vfend and Gaviscon. It is created by eHealthMe based on reports of 31 people who take the same drugs from the FDA, and is updated regularly.

What is Vfend?

Vfend has active ingredients of voriconazole. It is often used in aspergillosis. eHealthMe is studying from 12,128 Vfend users. Check the latest studies of Vfend.

What is Gaviscon?

Gaviscon has active ingredients of aluminum hydroxide; magnesium trisilicate. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 12,355 Gaviscon users. Check the latest studies of Gaviscon.

On Aug, 09, 2026

31 people who take Vfend and Gaviscon together, and have interactions are studied.

What are the common drug interactions of Vfend and Gaviscon, by gender? *:

female:

Fall
Cryoglobulinaemia (blood contains large amounts of cryoglobulins - proteins)
Ecchymosis (a discoloration of the skin resulting from bleeding underneath)
Oedema peripheral (superficial swelling)
Pain in extremity
Hepatocellular injury (liver injury)
Cutaneous vasculitis (an inflammatory process affecting the vessel wall that leads to its damage)
Sepsis (a severe blood infection that can lead to organ failure and death)
Thrombotic microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury)
Vasculitis (inflammation of a blood vessel or blood vessels)

male:

Abdominal pain
Balance disorder
Cardiac failure acute
Death
Hepatotoxicity (chemical-driven liver damage)
Hypernatraemia (an abnormally high plasma concentration of sodium ions)
Hypokalaemia (low potassium)
Nephropathy toxic (damage to kidney due to toxins)
Headache (pain in head)
Peripheral swelling

What are the common drug interactions of Vfend and Gaviscon, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Cryoglobulinaemia (blood contains large amounts of cryoglobulins - proteins)
Ecchymosis (a discoloration of the skin resulting from bleeding underneath)
Pain in extremity
Oedema peripheral (superficial swelling)
Cutaneous vasculitis (an inflammatory process affecting the vessel wall that leads to its damage)
Vasculitis (inflammation of a blood vessel or blood vessels)
Bronchial disorder
Oedema (fluid collection in tissue)
Superinfection

10-19:

Abdominal pain
Balance disorder
Headache (pain in head)
Peripheral swelling
Photosensitivity reaction
Sleep disorder

20-29:

Hepatotoxicity (chemical-driven liver damage)

30-39:

Hepatocellular injury (liver injury)
Cholestasis (a condition where bile cannot flow from the liver to the duodenum)

40-49:

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Leukopenia (less number of white blood cells in blood)

50-59:

Cardiac failure acute
Hypernatraemia (an abnormally high plasma concentration of sodium ions)
Hypokalaemia (low potassium)
Nephropathy toxic (damage to kidney due to toxins)

60+:

Fall
Sepsis (a severe blood infection that can lead to organ failure and death)
Anaemia (lack of blood)
Asterixis (flapping tremor, or liver flap)
Blood pressure immeasurable
Bradycardia (abnormally slow heart action)
Cardiac arrest
Coma (state of unconsciousness lasting more than six hours)
Death
Diarrhoea

What are the existing conditions these people have? *

Asthma: 7 people, 22.58%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 3 people, 9.68%
Pain: 3 people, 9.68%
Bronchopulmonary Aspergillosis (lung disorder caused by aspergillus fungi): 3 people, 9.68%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 3 people, 9.68%
Superinfection: 2 people, 6.45%
Herpes Virus Infection: 2 people, 6.45%
Anaemia (lack of blood): 2 people, 6.45%
Bleeding Into The Skin: 2 people, 6.45%
Cytomegalovirus Infection: 2 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Vfend and Gaviscon?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously